Mutations in the KRAS oncogene occur in 40% of colorectal cancers (CRC), and despite extensive investigation, KRAS mutated CRCs remain resistant to available targeted therapy strategies. Mutant KRAS has been linked to activation of multiple signaling pathways that promote cancer growth and survival including the MEK-ERK, PI3K and NF-?B pathways. Suppressing critical downstream signaling pathways, either alone or in combination, have evolved as promising treatment strategies. This proposal consists of innovative translational laboratory and clinical studies that focus on developing novel strategies to treat KRAS mutant CRCs. These investigations have already begun to yield strategies that will be assessed in clinical trials in this proposal. Our overarching aim is to substantively advance the treatment of KRAS mutant CRCs in this funding period. We have conducted comprehensive signaling studies, genetic screens, and drug screens to identify and validate genes downstream from KRAS whose expression is essential to the growth and survival of KRAS mutant cancers. Our analyses of 1000 cell lines treated with >200 drugs revealed that MEK inhibitors are the most effective class of agents against KRAS mutant CRC cell lines. However, single agent MEK inhibition appears minimally effective in clinical trial;as such we will develop novel combination strategies that utilize MEK inhibitors as a backbone for KRAS mutant CRC. We recently discovered that combining an IGF-IR inhibitor, which has minimal activity as a single-agent, with a MEK inhibitor is highly effective in KRAS mutant CRC cell lines in vitro and in vivo, leading to the development of a soon to open phase l/ll clinical trial of this combination. To discover additional combinatins, we developed an innovative pooled shRNA screen to identify MEK inhibitor-based combinations for KRAS mutant CRCs. One gene identified in the screen was BCL-XL, and initial studies demonstrate that inactivation of BCL-XL potently synergizes with MEK inhibitors both in vitro and in vivo, which we will further explore in the laboratory and in planned clinical trials. Finally, we will build on our preliminary data demonstrating that Tank Binding Kinase (TBK1) activity is required for KRAS mutant cell survival. We will examine combined TBK1 inhibitors alone and combined with MEK inhibitors. The studies in this proposal will span cell lines, genetically engineered mouse models and clinical trials to identify novel therapeutic strategies for the trea treament of KRS mutant CRCs.

Public Health Relevance

While treatment options have expanded for patients in the past decade and median survival is 2 years, metastatic colorectal cancer (CRC) is largely not curable and there are wide range of outcomes experienced by patients with metastatic CRC. It is clear that differences in outcomes are partly due to different molecular make-ups of tumors. Up to 40% of patients with metastatic CRC have a mutation of a particular gene, KRAS. The goal of this project is to understand more about this group of CRC and find new therapies for these patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-07
Application #
8933241
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Agarwal, Rajeev K
Project Start
2007-04-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$265,679
Indirect Cost
$60,788
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Schaefer, Inga-Marie; Wang, Yuexiang; Liang, Cher-Wei et al. (2017) MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun 8:14674
Larimer, Benjamin M; Wehrenberg-Klee, Eric; Dubois, Frank et al. (2017) Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res 77:2318-2327
Yang, Wanshui; Liu, Li; Masugi, Yohei et al. (2017) Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut :
Lopes-Ramos, Camila M; Paulson, Joseph N; Chen, Cho-Yi et al. (2017) Regulatory network changes between cell lines and their tissues of origin. BMC Genomics 18:723
Shi, Yan; Qian, Zhi Rong; Zhang, Sui et al. (2017) Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index. Pancreas 46:1347-1353
Keum, NaNa; Yuan, Chen; Nishihara, Reiko et al. (2017) Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. Int J Cancer 140:2648-2656
Lindström, Sara; Finucane, Hilary; Bulik-Sullivan, Brendan et al. (2017) Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiol Biomarkers Prev 26:1427-1435
Paulson, Joseph N; Chen, Cho-Yi; Lopes-Ramos, Camila M et al. (2017) Tissue-aware RNA-Seq processing and normalization for heterogeneous and sparse data. BMC Bioinformatics 18:437
Boland, C Richard; Yurgelun, Matthew B (2017) Historical Perspective on Familial Gastric Cancer. Cell Mol Gastroenterol Hepatol 3:192-200
Muranen, Taru; Iwanicki, Marcin P; Curry, Natasha L et al. (2017) Starved epithelial cells uptake extracellular matrix for survival. Nat Commun 8:13989

Showing the most recent 10 out of 543 publications